ENTA Profile
Enanta Pharmaceuticals, Inc. is a biotechnology firm specializing in the discovery and development of small molecule therapeutics aimed at treating viral infections and liver diseases. The company's research efforts are focused on developing innovative treatments for a range of infectious agents, including respiratory syncytial virus (RSV), SARS-CoV-2, human metapneumovirus (hMPV), and hepatitis B virus (HBV). Enanta's approach combines cutting-edge science with advanced drug development technologies to address significant unmet medical needs in these areas.
A key aspect of Enanta's business is its collaborative development and licensing agreement with Abbott Laboratories. This partnership is dedicated to identifying, developing, and commercializing protease inhibitors targeting the hepatitis C virus (HCV). Notable compounds from this collaboration include paritaprevir and glecaprevir, which are part of the treatment regimen for chronic hepatitis C. These drugs exemplify Enanta’s strategy of leveraging collaborative agreements to advance drug development and bring effective therapies to market.
In addition to its work on hepatitis C, Enanta Pharmaceuticals is actively engaged in the research and development of treatments for other viral infections. The company’s portfolio includes programs targeting RSV, a common respiratory virus with significant clinical implications, and SARS-CoV-2, the virus responsible for COVID-19. Enanta’s efforts in these areas are focused on developing novel therapeutic agents to improve patient outcomes and address the evolving challenges posed by viral diseases.
Founded in 1995 and headquartered in Watertown, Massachusetts, Enanta Pharmaceuticals has established itself as a leader in the field of antiviral and liver disease therapeutics. The company’s commitment to innovation and strategic partnerships underscores its role in advancing the science of drug development. By continuously expanding its research focus and leveraging collaborations, Enanta aims to deliver breakthrough therapies that address critical health challenges and enhance patient care globally.
|
